Group 1: Business Performance - In 2024, the company's main plant extraction business achieved a revenue of 1.725 billion yuan, with a gross margin of 28.09% [3] - The revenue ratio of stevia and monk fruit extract products is approximately 2:1 [3] - The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares, with a total expected payout of 72.6334 million yuan, representing 69.21% of the net profit attributable to shareholders over the past three years [4] Group 2: Market Strategy and Product Development - The company focuses on natural sweeteners and tea extracts as core products, implementing a "big product + N" strategy [3] - The company has made significant breakthroughs in synthetic biology technology, addressing supply instability and taste issues in monk fruit and stevia products [3] - The company is enhancing its domestic market presence for natural sweeteners, with a growing revenue share from domestic operations [9] Group 3: Impact of Tariffs and Trade Policies - Key products like stevia glycosides and monk fruit sweeteners have been included in the U.S. tariff exemption list, minimizing the impact of tariffs on the company [3][7] - The company is actively monitoring global trade policy changes and has initiated upgrades to its Indiana plant to mitigate tariff impacts [9][10] Group 4: Investor Relations and Shareholder Engagement - The company has a high response rate of over 98% to investor inquiries, emphasizing its commitment to transparency and communication [5] - A share repurchase plan has been implemented, with over 100 million yuan invested to buy back 15.2757 million shares, representing 2.06% of total shares [4][5] Group 5: Future Outlook and Industry Trends - The plant extraction industry is expected to experience robust growth due to rising health awareness and supportive government policies [17][18] - The company anticipates that its synthetic biology production line will achieve an annual output value exceeding 1 billion yuan once fully operational [19]
莱茵生物(002166) - 002166莱茵生物投资者关系管理信息20250417